The past year emphasised the strength and world-leading capabilities of the UK cell and gene therapy industry which experienced significant expansion despite the COVID-19 pandemic.
The Cell and Gene Therapy Catapult has published its 2021 Annual Review, highlighting that the UK has become a place of choice to set up advanced therapy medicinal products (ATMP) activities, with 29% of European ATMP companies operating in the country.
Click here to read the Cell and Gene Therapy Catapult’s Annual Review 2021.
Copyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.